ArticleTherapeutic advances in medical oncology2010
Targeted therapies in small cell lung cancer: a review.
Article in Therapeutic advances in medical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Activating Invasion and Metastasis in Small Cell Lung Cancer: Role of the Tumour Immune Microenvironment and Mechanisms of Vasculogenesis, Epithelial-Mesenchymal Transition, Cell Migration, and Organ Tropism.Cancer reports (Hoboken, N.J.) · 2024Review
- Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers.Journal of the Chinese Medical Association : JCMA · 2022Review
- Small Cell (Neuroendocrine) Carcinoma of the Cervix: An Analysis for 19 Cases and Literature Review.Frontiers in cellular and infection microbiology · 2022Review
- FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.The oncologist · 2021Review
- Combination therapy: Future directions of immunotherapy in small cell lung cancer.Translational oncology · 2021Review
- Article
- ADAMTS-1 inhibits angiogenesis via the PI3K/Akt-eNOS-VEGF pathway in lung cancer cells.Translational cancer research · 2019Article
- High CTHRC1 expression may be closely associated with angiogenesis and indicates poor prognosis in lung adenocarcinoma patients.Cancer cell international · 2019Article
- ProGRP as early predictive marker of non-small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment.Respiratory medicine case reports · 2019Article
- Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.The American journal of surgical pathology · 2018Article
- The Economic Burden of Small Cell Lung Cancer: A Systematic Review of the Literature.PharmacoEconomics - open · 2018Review
- Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models.Oncotarget · 2018Article
- A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness.Oncogene · 2017Article
- An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients.Clinical & experimental metastasis · 2016Article
- Farnesiferol c induces apoptosis via regulation of L11 and c-Myc with combinational potential with anticancer drugs in non-small-cell lung cancers.Scientific reports · 2016Article
- Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice.BMC research notes · 2015Article
- Small Cell Carcinoma of the Gallbladder: Case Report and Comprehensive Analysis of Published Cases.Journal of oncology · 2015Review
- Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients.British journal of cancer · 2013Article
- Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer.Drug design, development and therapy · 2013Review
- FDG PET/CT metabolic tumour volume in small-cell lung cancer: better staging and prognostic stratification for an improved therapeutic strategy.European journal of nuclear medicine and molecular imaging · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that is characterized by a rapid doubling time, early onset of dissemination and high sensitivity to chemotherapy. Despite the potential for cure in patients with limited disease with concurrent chemoradiation and an initial good response to chemotherapy in extensive disease, there is a high chance of disease relapse with an overall poor median survival for both stages. With increasing translational research and a better understanding of the molecular basis of cancer, a number of molecular targets have been identified in various preclinical studies. This review summarizes potentially viable targets and new agents that have been developed and employed in recent, ongoing and future clinical trials to attempt to improve clinical outcomes in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.